Skip to main content

Johnson & Johnson Vaccine Has Jim Cramer Watching the Reopening Trade

Publish date:
Video Rating:
Video Duration:

Johnson & Johnson's  (JNJ) - Get Johnson & Johnson Report COVID-19 vaccine candidate won FDA support ahead of its emergency use authorization meeting.

"Safety analysis through the January 22, 2021 data cutoff included 43,783 randomized (1:1) participants ≥18 years of age with 2-month median follow-up," the FDA briefing notes said. "The analysis supported a favorable safety profile with no specific safety concerns identified that would preclude issuance of an EUA."

"Non-fatal serious adverse events, excluding those attributed to COVID-19, were infrequent and balanced between study groups with respect to rates and types of events (0.4% in both groups)," the FDA added. "One serious event of a hypersensitivity reaction, not classified as anaphylaxis, beginning two days following vaccination was likely related to receipt of the vaccine." 

Recap TheStreet Live: Everything Jim Cramer Is Watching in the Markets Wednesday

Curious about what Jim Cramer and his team at Action Alerts PLUS are watching in the markets? Watch Cramer's exclusive members-only Daily Rundown show on Action Alerts PLUS following TheStreet Live.

Related Videos